Jubilant Pharmova’s Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The standalone results reflect a shift in operations following the sale of the API business. Consolidated results show revenue growth, but also increased expenses related to specific operational challenges. The company is monitoring the impact of new labor codes on its financial performance.
Financial Performance Overview
Jubilant Pharmova Limited announced its unaudited financial results for the third quarter (Q3) of the Indian Financial Year 2026, ending on December 31, 2025. The Board of Directors approved these results on February 6, 2026. The announcement details both standalone and consolidated financial performance, reflecting significant operational changes within the company.
Standalone Financial Highlights
Key points from the standalone results include:
- Total revenue from operations stood at ₹673 million for Q3 2026.
- Net profit for the period was ₹66 million.
- The results reflect the classification of the Active Pharmaceutical Ingredients (API) business as a discontinued operation following its sale to Jubilant Biosys Limited on September 1, 2025.
Consolidated Financial Highlights
The consolidated results reveal the performance of Jubilant Pharmova including its subsidiaries and associates:
- Total revenue from operations reached ₹21,225 million for Q3 2026, compared to ₹19,664 million in Q3 2025.
- Net profit for the period was ₹558 million.
- The company recognized exceptional expenses primarily related to the temporary suspension of operations at a contract manufacturing facility and amortization of debt initiation costs.
Segment Performance
A breakdown of segment-wise revenue shows:
- Radiopharma generated revenue of ₹9,344 million.
- Allergy Immunotherapy contributed ₹1,927 million.
- Contract Development and Manufacturing Organisation – Sterile Injectables reported ₹4,620 million.
- Contract Research, Development and Manufacturing Organisation revenue was ₹3,062 million.
- Generics segment revenue was ₹2,261 million.
Other Key Considerations
The company is also closely monitoring the implementation of new labor codes in India and assessing their potential impact on gratuity and compensated absence expenses. While the Finance Bill, 2026 proposes changes to Minimum Alternate Tax (MAT) credit utilization, no adjustments have been made pending its enactment.
Source: BSE
